Cost-Utility Model of Nirmatrelvir/Ritonavir in Brazil: Analysis of a Vaccinated Population

Article Immunology

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Ronza Najjar-Debbiny et al.

Summary: This study assessed the effectiveness of Paxlovid in high-risk COVID-19 patients in real-world settings. The findings demonstrate that Paxlovid is highly effective in reducing the risk of death and severe COVID-19 in the Omicron era. The study also suggests that Paxlovid may be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease. Vaccination status did not significantly impact the effectiveness of Paxlovid.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Article Immunology

Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-19)

Sarju Ganatra et al.

Summary: In this observational analysis, treatment with nirmatrelvir plus ritonavir in nonhospitalized vaccinated patients at high risk of disease progression was associated with a significantly reduced likelihood of emergency room visits, hospitalization, or death between days 10 and 30, with no apparent increase in serious complications.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea

Youngji Jo et al.

Summary: This study in Korea assessed the cost-effectiveness of oral antiviral agents for COVID-19 treatment. The results showed that using nirmatrelvir/ritonavir for elderly patients with COVID-19 would be highly cost-effective and significantly reduce the burden on the healthcare system.

EPIDEMIOLOGY AND HEALTH (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022

Melisa M. Shah et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Immunology

Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing-A Cost-effectiveness Analysis

Alexandra Savinkina et al.

Summary: This study conducted a cost-effectiveness analysis of prescription policy strategies for nirmatrelvir/ritonavir using a decision-analytic model. The results suggest that providing this drug to unvaccinated high-risk patients is cost-effective. The cost-effectiveness of other allocation strategies depends on various factors.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Review Virology

The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Chih-Cheng Lai et al.

Summary: This network meta-analysis compared the clinical efficacy and safety of antiviral agents for non-hospitalized COVID-19 patients. The results showed that nirmatrelvir plus ritonavir was the best treatment, followed by remdesivir and then molnupiravir. These agents did not increase the risk of adverse events compared to placebo.

VIRUSES-BASEL (2022)

Add to Collection

Article Virology

Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation

Stephen J. Halpin et al.

Summary: This study is the first report from the United Kingdom on post-discharge symptoms in COVID-19 survivors, identifying fatigue, breathlessness, and psychological distress as common symptoms that require planning of rehabilitation services for appropriate management.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19

Maxime Taquet et al.

Summary: This study investigated the incidence and co-occurrence of long-COVID features in COVID-19 survivors, with comparisons to influenza patients, using electronic health records data. The findings showed that long-COVID clinical features were more commonly reported after COVID-19 infection, and differences were associated with sex, age, and illness severity.

PLOS MEDICINE (2021)

Add to Collection

Article Urology & Nephrology

Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis

Shelief Y. Robbins-Juarez et al.

Kidney International Reports (2020)

Add to Collection

Cost-Utility Model of Nirmatrelvir/Ritonavir in Brazil: Analysis of a Vaccinated Population

Related references

Export Citation

Share Paper